Brief: TG Therapeutics Announces Data Presentations From The Ultimate I & II Phase 3 Trials Of Briumvi (Ublituximab) In Multiple Sclerosis To Be Presented
14/02/2023 12:43
Feb 14 (Reuters) - TG Therapeutics Inc TGTX.O :
* TG THERAPEUTICS ANNOUNCES DATA PRESENTATIONS FROM THE
ULTIMATE I
& II PHASE 3 TRIALS OF BRIUMVI™ (UBLITUXIMAB) IN MULTIPLE
SCLEROSIS TO BE PRESENTED AT THE AMERICAS COMMITTEE FOR
TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS ANNUAL FORUM
Source text for Eikon: ID:nGNXbmgVN6
Further company coverage: TGTX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on TG Therapeutics
See all newsTG Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tg Therapeutics Reports Second Quarter 2026 Financial Results And Raises Briumvi® Revenue Guidance
TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj